CSIMarket Company Name, Ticker, Competitors, else..
 
Burzynski Research Institute Inc  (NONE: BZYR)
Other Ticker:  
 
 
Price: $0.0450 $0.00 -8.163%
Day's High: $0.05 Week Perf: 48.51 %
Day's Low: $ 0.05 30 Day Perf: 45.16 %
Volume (M): 13 52 Wk High: $ 0.08
Volume (M$): $ 1 52 Wk Avg: $0.04
Open: $0.05 52 Wk Low: $0.03



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 131
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Burzynski Research Institute Inc
Burzynski Research Institute Inc is a biomedical research institution located in Houston, Texas. It was founded by Dr. Stanislaw Burzynski in 1976. The institute is primarily focused on researching and developing innovative oncology treatments.

Burzynski Research Institute is best known for its controversial treatment called Antineoplaston therapy. This therapy claims to target and destroy cancer cells by using a combination of naturally occurring peptides and amino acid derivatives. However, the effectiveness and safety of this treatment have been a subject of debate among the medical community.

In addition to Antineoplaston therapy, the institute also conducts research on other treatment methods for various types of cancers, including personalized gene-targeted therapy and targeted chemotherapy. It aims to provide alternative treatment options for patients who have exhausted conventional treatment options.

Over the years, Burzynski Research Institute has faced scrutiny from regulatory authorities and skeptics due to concerns about the scientific validity of its experimental treatments, patient safety, and ethical issues related to its clinical trials. However, it has also garnered support from patients and their families who claim to have experienced positive outcomes from the institute's treatments.

Overall, the Burzynski Research Institute Inc has gained both recognition and controversy for its unconventional cancer treatments and research efforts.


   Company Address: 9432 Katy Freeway Houston 77055 TX
   Company Phone Number: 335-5697   Stock Exchange / Ticker: NONE BZYR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CLDX        11.94% 
AMGN   -3.04%    
BIIB        2.99% 
GILD        0.88% 
MRNA   -1.61%    
REGN   -3.26%    
• View Complete Report
   



Burzynski Research Institute Inc

Burzynski Research Institute Inc, Unveiling Troubling Patterns in Company Conduct during Fiscal First Quarter of 2024

Burzynski Research Institute Inc, a publicly traded company, recently released its financial results for the fiscal period ending on May 31, 2024. The shareholders were surprised by the lack of revenue growth during this earnings cycle, which was unexpected considering the company's previous performance. The operating loss for the period was reported to be $-0.371332 million, which is a significant increase from the previous quarter's operating loss of $-0.287405 million.
Although the company did not disclose its top-line revenue figures for the period, it is clear that Burzynski Research Institute Inc is facing challenges in terms of profitability. The net loss for the period also increased to $-0.371 million, indicating a downward trend in the company's financial performance.
Burzynski Research Institute Inc

New Financial Report Reveals Operating Loss for Burzynski Research Institute Inc in Fourth Quarter of 2024

The In Vitro & In Vivo Diagnostic Substances sector has been closely monitoring the fourth quarter results of various companies, including the Burzynski Research Institute Inc. In their most recent report, the company disclosed an operating loss of $-0.362907 million for the reporting season of December to February 29, 2024. This is a contraction from the operating loss of $-0.215998 million reported in the fourth quarter of 2023.
Despite the decrease in operating loss, Burzynski Research Institute Inc has not cited any revenue so far, leaving market participants speculating on when the company may begin to see revenue coming in. The company also reported a net loss of $-0.363 million, which has extended from $-0.216 million in the fourth quarter of 2023.
Burzynski Research Institute Inc

Burzynski Research Institute Inc Faces Operating Shortfall, Raises Stockholder Concerns



Burzynski Research Institute Inc (BZYR) has recently experienced modifications in its business during the earnings cycle of fiscal September to November 30, 2023. These unexpected changes have sparked concerns among stockholders, especially regarding the company's operating shortfall. This article aims to provide an explanatory analysis of the operating shortfall, explore its implications on the company's revenue, and discuss the context provided by previous financial performance.
Operating Shortfall Overview:
During the specified period, BZYR reported an operating shortfall of $-0.433015 million. This indicates that the company's operating expenses exceeded its revenue, resulting in a negative financial outcome. It is important to note that BZYR has not yet disclosed its revenue figures for this period, but it is crucial to consider the previous financial performance to gain a broader understanding of the situation.
Burzynski Research Institute Inc

Burzynski Research Institute Inc Stands Out as a Rising Power Player in In Vitro & In Vivo Diagnostic Substances Market, Revealing Q2 2024 Financial Results

Burzynski Research Institute Inc Shows Promise with Rising Revenues Despite Operating Loss in Q2 2024
In the In Vitro & In Vivo Diagnostic Substances sector, Burzynski Research Institute Inc, a smaller corporation, has been making impressive strides in terms of revenue growth. While the company recently reported an operating loss of $-0.252104 million for the second quarter of 2024, it is important to examine the larger picture and consider the company's performance in comparison to previous years.
Although the exact revenue figures have not yet been disclosed, it is crucial to assess the company's progress by looking at its performance during the second quarter of 2023. Back then, Burzynski Research Institute Inc recorded an operating loss of $-0.215918 million. Despite the slight increase in the operating loss for Q2 2024, it is worth noting that the company's management, spearheaded by the CFO, is actively seeking various corporate policies to ensure a steady product line. This strategic focus aims to address any shortfall the company has experienced throughout its emerging cycle.
Burzynski Research Institute Inc

Accruing Operating Expenditure Arises as Critical Headache for Biotech Firm in Fiscal Period Concluding May 31, 2023

Burzynski Research Institute Inc, a prominent player in the Biotechnology & Pharmaceuticals industry, recently released its financial earnings for the first quarter of 2024. The company reported an operating deficit of $-0.287405 million during this period. While the revenue has not been disclosed yet, it is worth noting that in the first quarter of 2023, the company reported an operating deficit of $-0.231737 million.
The financial results for the period ending May 31, 2023, highlight a widened shortfall compared to the previous year. The loss has increased from $-0.232 million in the first quarter of 2023 to $-0.287 million in the first quarter of 2024. This indicates that the company has faced challenges in generating revenue and is currently operating at a deficit.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com